$0.8200
-0.05-5.60%
At close: -
$0.8001
-0.02-2.43%
After Hours: Apr 4, 7:50 PM EDT
Comments
Loading...
Moleculin Biotech Analyst Ratings and Price Targets | NASDAQ:MBRX | Benzinga
Moleculin Biotech Inc has a consensus price target of $14.25 based on the ratings of 4 analysts. The high is $40 issued by Roth MKM on April 12, 2024. The low is $4 issued by Maxim Group on March 25, 2025. The 3 most-recent analyst ratings were released by Maxim Group, HC Wainwright & Co., and HC Wainwright & Co. on March 25, 2025, March 25, 2025, and March 24, 2025, respectively. With an average price target of $6.67 between Maxim Group, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 733.23% upside for Moleculin Biotech Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
HC Wainwright & Co.
Roth MKM
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Moleculin Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | 399.94% | Maxim Group | Jason McCarthy41% | → $4 | Upgrade | Hold → Buy | Get Alert |
| 03/25/2025 | Buy Now | 899.88% | HC Wainwright & Co. | Vernon Bernardino47% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/24/2025 | Buy Now | 899.88% | HC Wainwright & Co. | Vernon Bernardino47% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 899.88% | HC Wainwright & Co. | Vernon Bernardino47% | $8 → $8 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 899.88% | Maxim Group | Jason McCarthy41% | $20 → $8 | Maintains | Buy | Get Alert |
| 04/12/2024 | Buy Now | 4899.38% | Roth MKM | Jonathan Aschoff34% | → $40 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 2399.69% | Maxim Group | Jason McCarthy41% | $45 → $20 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 274.95% | HC Wainwright & Co. | Vernon Bernardino47% | → $45 | Initiates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 1899.75% | Roth MKM | Jonathan Aschoff34% | → $240 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | 524.92% | Oppenheimer | Jeff Jones32% | → $75 | Reiterates | → Outperform | Get Alert |
| 07/18/2022 | Buy Now | 1649.78% | Oppenheimer | Jeff Jones32% | $30 → $210 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Moleculin Biotech (MBRX) stock?
The latest price target for Moleculin Biotech (NASDAQ:MBRX) was reported by Maxim Group on March 25, 2025. The analyst firm set a price target for $4.00 expecting MBRX to rise to within 12 months (a possible 399.94% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Moleculin Biotech (MBRX)?
The latest analyst rating for Moleculin Biotech (NASDAQ:MBRX) was provided by Maxim Group, and Moleculin Biotech upgraded their buy rating.
When was the last upgrade for Moleculin Biotech (MBRX)?
The last upgrade for Moleculin Biotech Inc happened on March 25, 2025 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Moleculin Biotech Inc.
When was the last downgrade for Moleculin Biotech (MBRX)?
There is no last downgrade for Moleculin Biotech.
When is the next analyst rating going to be posted or updated for Moleculin Biotech (MBRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moleculin Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moleculin Biotech was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Moleculin Biotech (MBRX) correct?
While ratings are subjective and will change, the latest Moleculin Biotech (MBRX) rating was a upgraded with a price target of $0.00 to $4.00. The current price Moleculin Biotech (MBRX) is trading at is $0.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.